Protein Structure Analytics in Developing Biopharmaceuticals
Dr. Steven Berkowitz, Ph.D., together with Dr. Jared Auclair, Ph.D., will host a one-day intense general survey course covering the integration of the various roles protein structure analysis (primary to quaternary) tools play in the development process of a biopharmaceutical. Significant emphasis will be placed on the separation sciences, physicochemical structural characterization and the global role of Mass Spectroscopy (MS) in the analysis of post-translational modifications, higher order structure (HOS), aggregation and degradation.
This course offers the unprecedented opportunity to gain a rapid overview and concise insights into the tools of protein structural analysis and how they are used in developing biopharmaceuticals. Note attendance is limited to ensure an interactive environment for learning.
Course Overview (click here for a tentative schedule)
- Lectures will include an overall view of protein structure and the staging of its analysis within the industry to assess this information using an array of analytics in developing biopharmaceuticals
- Opportunity for round table discussions guided by the specific interests of those attending the meeting on general or specific topics concerning contemporary biopharmaceutical development (e.g. comparability and biosimilarity).
- Demonstrations of primary structure analysis (post-translational modifications) using mass spectrometry and the analysis of aggregation using analytical ultracentrifugation will be included.
About the Course Speakers
Steven A. Berkowitz, Ph.D., Principal Investigator, Analytical/Purification/Formulation Development, Biogen, Inc. (retired) received a B.S. degree in Biology from Fairleigh Dickinson University and a Ph.D. degree in Biochemistry from New York University. He then spent several years as a post-doctoral fellow at Yale University and the NIH. After his post-doctoral work Dr. Berkowitz held various positions at Celanese Research Company, J.T. Baker, Lederle Laboratories and Biogen where he spent his last 20 years. Dr. Berkowitz’s technical areas of expertise are concentrated in the separation sciences and the physical sciences associated with the characterization of biopolymers and synthetic polymers. Much of Dr. Berkowitz’s work has centered on assessing the physicochemical properties, heterogeneity and aggregation properties of biopharmaceuticals using light scattering, analytical ultracentrifugation, chromatography, electrophoresis, and various forms of spectroscopy.
Jared R. Auclair, Ph.D. is currently a senior research scientist in the department of chemistry and chemical biology as well as in the laboratory of Professor Jeffrey Agar and Professor William Hancock. In addition, Dr. Auclair has a courtesy post-doc appointment in the lab of Professor Gregory Petsko (Weill Cornell Medical School) and Professor Dagmar Ringe (Brandeis University). He has expertise in mol. biology, protein biochemistry, analytical chemistry, protein crystallography, and biological mass spectrometry; and is interested in understanding the molecular mechanisms of neurodegenerative diseases in order to develop novel therapeutic approaches.
Reasons to Attend
- Learn the role protein structure (primary to quaternary) play in mastering the complex process of developing a successful biopharmaceutical.
- Explore current analytical methods and strategies used for a wide range analysis on proteins that include such standard tools such as size-exclusion chromatography, electrophoresis, light scattering, analytical ultracentrifugation, mass spectrometry (including H/DX) and NMR
- Understand the capability, limitation and pitfalls of these techniques.
Location: Biopharmaceutical Analysis Training Lab, 145 S Bedford St, Burlington; Northeastern University’s Burlington Innovation Campus (just north of Boston)
Registration Fee: $ 700 Course fee includes all course materials, refreshments and luncheons